Professional Skin Pad
- Known as:
- Professional Skin Pad
- Catalog number:
- KMMS151
- Category:
- -
- Supplier:
- Kemaj
- Gene target:
- Professional Skin Pad
Related genes to: Professional Skin Pad
- Gene:
- CCL27 NIH gene
- Name:
- C-C motif chemokine ligand 27
- Previous symbol:
- SCYA27
- Synonyms:
- ALP, ILC, CTACK, skinkine, ESkine, PESKY, CTAK
- Chromosome:
- 9p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-07-30
- Date modifiied:
- 2016-10-05
Related products to: Professional Skin Pad
3-D Platform Shaker base, with platform and non-slip rubber pad, 120V3-D Platform Shaker base, with platform and non-slip rubber pad, 240V3-D Platform Shaker base, with platform and non-slip rubber pad, 240V, CE3-D Platform Shaker, with platform and non-slip rubber pad, 120V3-D Platform Shaker, with platform and non-slip rubber pad, 120V3-D Platform Shaker, with platform and non-slip rubber pad, 240V3-D Platform Shaker, with platform and non-slip rubber pad, 240V3-D Platform Shaker, with platform and non-slip rubber pad, 240V, CE3-D Platform Shaker, with platform and non-slip rubber pad, 240V, CEA-431 Cell Slide (Human (85 yrs, Female) skin epidermoid carcinoma) (5 slides pk)Adapter (Bottom Pad) 16 ml Rotor bore per 1 x 12 per 15 ml glass tubes (Adapter (Bottom Pad) 16 ml Rotor bore / 1 x 12/15 ml glass tubes (Ø 18 mm)Adapter (Bottom Pad) 16 ml Rotor bore _ 1 x 12_15 ml glass tubes (Adapter (Bottom Pad) 16 ml Rotor bore _ 1 x 12_15 ml glass tubes (Ø 18 mm)Adapter (Bottom Pad) 250 ml Rotor bore per 1 x 200 ml glass tubes Related articles to: Professional Skin Pad
- My research has focused on optimizing drug delivery system (DDS) related gene and cell therapies. In my gene therapy research, I first developed a polyethylene glycol (PEG)-conjugated adenovirus vector (PEG-Ad) to allow modulation of adenovirus pharmacokinetics and achieve tumor targeting. Evaluating correlations between PEG-Ad blood retention, tumor tissue delivery, liver accumulation, and gene expression is an important step toward creating tumor-targeting PEG-Ad, demonstrating that a 90% PEGylation rate optimally reduced liver accumulation and improved tumor targeting via enhanced permeability and retention. To enhance tumor targeting specificity, we designed Cys-Gly-Lys-Arg-Lys (CGKRK)-PEG-Ad, in which the tumor-targeting peptide CGKRK was attached to the end of the PEG chain. Although CGKRK-PEG-Ad exhibited similarly reduced liver accumulation to that of PEG-Ad, its tumor delivery was higher than that of PEG-Ad, demonstrating its potent therapeutic efficacy against metastatic tumors. Next, I worked to optimize tumor immunotherapy by controlling immune cells in vivo dynamics. In this study, cytokines were used to activate antitumor immune cells, and chemokines were used to induce intratumoral infiltration by antitumor immune cells. While intratumoral administration of Arg-Gly-Asp (RGD)-Ad-C-C motif chemokine ligand 27 (CCL27) alone did not produce an antitumor effect against OV-HM tumors; however, co-administration with RGD-Ad-interleukin-12 (IL-12) demonstrated a stronger antitumor effect than administration of RGD-Ad-IL-12 alone. Infiltration of cluster of differentiation 3 (CD3)- and perforin-positive cells into tumor tissues was increased by combined administration of RGD-Ad-CCL27 and RGD-Ad-IL-12 compared with administration of RGD-Ad-IL-12 alone. These results demonstrate the importance of controlling the in vivo dynamics of antitumor immune cells. - Source: PubMed
Nakagawa Shinsaku - Osimertinib is a primary treatment for patients with EGFR-mutated non-small cell lung cancer. But a significant number of patients receiving Osimertinib treatment suffer from cutaneous toxicity, which includes symptoms such as rash, itching, and hair loss. This study aims to help clinical patients suffering from cutaneous toxicity to improve their quality of life. Mice treated with 50 mg/kg/day Osimertinib for 42 days exhibited different levels of cutaneous toxicity. PI/Annexin-V apoptosis assay and western blotting were used to assess keratinocyte apoptosis and DNA damage. Osimertinib upregulated inflammatory factors including CCL2, CCL27, and IL18. Glycyrrhizic acid (GA) is the most important active ingredient in licorice with pharmacological effects such as anti-inflammatory, antiviral, and anti-apoptotic. Due to its rich bioactivity, the research about GA has always been popular. However, the effects of it on relieving cutaneous toxicity have not been studied yet. We have explored the therapeutic effects and mechanisms of GA on keratinocytes and C57BL/6 mice. Thirty milligrams/kg/day of GA could effectively reduce the frequency and severity of cutaneous toxicity induced by Osimertinib, restore epidermal thickness in mice, reduce DNA damage, and lower the expression levels of inflammatory factors. Our results indicated that GA could potentially mitigate the cutaneous toxicity caused by Osimertinib, which could position it as a promising adjunct in clinical practice. - Source: PubMed
Publication date: 2026/04/01
Wang CongyingLu JiabinFu HuangxiFeng XuejingXu ZhifeiLuo PeihuaYang BoHe QiaojunYang Xiaochun - Psoriasis is a refractory immune-related disease. In recent years, it has been discovered that mesenchymal stem cells (MSCs) can be used as a new therapeutic approach for psoriasis, but their potential therapeutic mechanism remains unclear. This study aims to explore the role of MSCs in the treatment of psoriasis. - Source: PubMed
Publication date: 2026/03/28
Lin QingJi YunfeiYang BinZhu RongjiaSong PingZhao Robert Chunhua - Ceramide deficiency in the stratum corneum (SC) is a key etiological factor in atopic dermatitis (AD). To clarify the direct role of SC ceramide depletion in impairing SC barrier and water-holding functions and in initiating AD-like skin symptoms and disease-specific molecular alterations, we generated Tg mice overexpressing a mutant form of acid ceramidase (aCDase) under the control of the involucrin promoter, resulting in targeted expression in the upper epidermis. By 3 weeks of age, Tg mice developed noninflammatory, scaly skin characterized by severely compromised barrier integrity and water-holding capacity, along with significantly elevated epidermal aCDase activity and markedly reduced ceramide levels in the SC. Compared to WT controls, Tg mice also exhibited increased epidermal innervation and reduced intraepidermal semaphorin 3a protein levels. Additionally, Tg skin showed substantial changes in the expression of AD-associated biomarkers involved in barrier impairment, pruritus, and Th2 polarization. These included increased levels of Il10, Il17a, S100a7, S100a8, and S100a9 and decreased levels of Cxcl10, Ifng, Il2, Il13, Il33, Sema3a, and Tlr9. Repeated topical application of mite antigens induced allergic responses in Tg mice, but not in WT mice. These responses were characterized by prominent eosinophil infiltration in the dermis and significantly elevated serum IgE levels. Allergen-challenged ear skin from Tg mice also demonstrated significantly increased expression of inflammatory mediators related to AD, including Ccl17, Ccl22, Ccl26, Ccl27, Il3, Il13, Il22, and Il33. These findings establish Tg mice as a pathophysiologically relevant model of AD, presenting key features such as xerotic, pruritic skin, impaired barrier and water-retention functions, and Th2-dominant allergic inflammation. This model provides important insights into ceramide-dependent mechanisms in AD pathogenesis and offers a useful platform for therapeutic development. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. - Source: PubMed
Publication date: 2026/03/24
Takada MarikoSashikawa-Kimura MihoOhno YusukeHossain Md RazibXie XiaonanIwabuchi KazuhisaKomine MayumiOhtsuki MamitaroImokawa Genji - Targeted treatments for non-communicable chronic inflammatory skin diseases like eczema and psoriasis offer significant potential for effective therapy. However, therapeutic success requires an accurate diagnosis, which is challenging due to their overlapping clinical and histological features. - Source: PubMed
Publication date: 2026/03/12
Schmitt AndreaProksch SusanneGutzweiler LudwigRoth SandraEngler MarcellaMüller Cornelia S LVolz AndreasArnold Andreas WŠedivcová MonikaBernklauova AdrianaDura MiroslavKacerovska DenisaTechnau-Ihling KatjaIhling ChristianRakozy ChristianePruessmann WiebkeLeibing Thomasvon Eichborn Maria IsabelKern JohannesOms ElisabethEyerich StefanieEyerich KilianLaaff HelmutGarzorz-Stark NatalieTechnau-Hafsi Kristin